Scilex Holding Company Common Stock (SCLX)

FairStock Score: 19/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I want a durable business with predictable earnings and a margin of safety. Scilex fails most tests. It has commercial non-opioid pain products, and fiscal 2025 revenue was $30.3M, but that was down from $56.6M in fiscal 2024. The losses are staggering: net income was -$374.1M in fiscal 2025, and in fiscal Q2 2026, the quarter ended 2026-06-30, the company reported revenue of $7.6M against a net loss of $115.0M. That is not a temporary stumble; it has lost money in each of the last four years, which is why the FairStock Lynch category is 'none.' Operating metrics confirm distress. On FairStock's calculations, ROCE is -105.83%, free cash flow is -$18.4M, and FCF yield is -75.3% of the $24.5M market cap at the 2026-10-13 close. The FairStock-calculated Altman Z-Score of -8.53 and Piotroski F-Score of 3/9 point to balance-sheet and profitability weakness. At the 2026-10-13 close, the FairStock-calculated P/E is -0.06, so earnings give no valuation anchor. The 52-week range of $2.79-$27.00 shows how far the stock has fallen, but a falling price alone is not value. A tiny market cap does not create a moat; it often reflects financing risk and dilution. I see no margin of safety here. The products may help patients, but as an investment the company must first show stable revenue, narrower losses, and positive cash generation.

In plain English: Scilex sells prescription pain products, including ZTlido and ELYXYB, for non-opioid pain and migraine. The business looks weak: revenue fell in fiscal 2025, losses are very large, and the company is using more cash than it brings in. Because it is losing money and burning cash, the stock does not look cheap compared with its financial results, even at a small market value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer